港股異動丨多重利好疊加,維他奶再度拉昇升超6%
昨日一度暴升超39%的維他奶(0345.HK)再度拉昇升超6%,現報12.34港元,總市值132億港元。消息上,公司日前公佈中期業績顯示,收益為34.43億港元,同比增長1.54%;股東應占期內盈利為1.71億港元,同比增長4.82%。麥格理上調維他奶目標價至10.7港元,稱其盈利可見性正提升。此外,信和置業主席黃志祥胞弟黃志達申報,於11月21日在場內買入410萬股維他奶,涉資4229萬港元。據悉,10月以來,其持續通過旗下楊協成(新加坡上市飲品公司)及家族辦公室增持維他奶。當月初,其持股比例尚且不足5%,目前比例增至12.26%。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.